Multidisciplinary Therapy of Pancreative Cancer: Recent Advances and Emerging Paradigms

Multidisciplinary Therapy of Pancreative Cancer: Recent Advances and Emerging Paradigms is organized by The University of Texas MD Anderson Cancer Center and will be held from May 03 - 04, 2019 at The University of Texas MD Anderson Cancer Center, Houston, Texas, United States of America.

Target Audience:
This conference should be of interest to Physicians, Advanced Practice Providers, Nurses, Researchers, Fellows and Trainees.

Accreditation/Credit Designation:
The University of Texas MD Anderson Cancer Center designates this live activity for a maximum of 10.50 AMA PRA Category 1 Credits™.  Physicians should claim only the credit commensurate with the extent of their participation in the activity.

ABIM Maintenance of Certification (MOC):
Successful completion of this CME activity, which includes participation in the evaluation component, enables the participant to earn up to 10.50 Medical Knowledge MOC points in the American Board of Internal Medicine’s (ABIM) Maintenance of Certification (MOC) program.

Ethics:
The “Supportive Care” session has beendesignated by The University of TexasMD Anderson Cancer Center for .75 AMAPRA Category 1 Credits™ in medical

Goal:
Educational ObjectivesThis activity will present new treatment options to physicians and affiliated health professionals for patients with pancreatic cancer. In addition, multidisciplinary case studies will be presented highlighting optimal approaches to complex scenarios in this disease. The long-term goal of these efforts is to improve the survival rate of pancreatic cancer patients through evidence based approaches.

After attending the conference, participants should be able to:
• Implement genetic testing of patients and family members to screen for those who are at risk for developing pancreatic cancer and other cancers (knowledge, competence, performance, patient outcomes);
• Evaluate, counsel and treat patients with pancreatic cancer at all stages of disease (locally advanced, resectable, borderline resectable, metastatic) (knowledge, competence, performance, patient outcomes);
• Provide a comprehensive understanding of innovative and emerging cancer therapies, inclusive of the side effects, to the cancer patient (knowledge, competence, performance, patient outcomes); and
• Apprise fellow clinicians and healthcare providers of emerging paradigms of the latest clinical trials and supportive care (knowledge, competence, performance, patient outcomes).

Educational Methods:
• Lectures
• Case Study
• Questions-and-Answer Session